In English | En español
Questions About Cancer? 1-800-4-CANCER
American Reinvestment and Recovery Act

Page Options

  • Print This Page
  • Email This Document

Additional Recovery Act Resources from NIH

NIH and the Recovery Act
NIH RePORT

Clinical Trials Supported by Accelerating Clinical Trials of Novel Oncologic PathWays (ACTNOW) Initiative

ACTNOW is an early-phase clinical trial program designed to help shorten the time it takes to move new cancer treatments from the discovery phase, to drug development, and, ultimately, to approval and safe use by cancer patients.

The table below lists the ACTNOW trials by cancer type, and contains links to descriptions of the drugs being studied, the trial objectives, patient enrollment criteria, and locations where patients receive treatment.

Disease(s)Study Drug /
Therapy
Protocol ID /
Title
Lead Organization
Brain tumorCediranibLaboratory and imaging studies related to 8030,
Phase I/II Study of Cediranib, Temozolomide, and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Massachusetts General Hospital, Dana-Farber Cancer Institute
Brain tumorCediranib CilengitideABTC-0903
A Phase Ib Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma
Adult Brain Tumor Consortium
Brain tumorGDC-0449ABTC-0904
A Biomarker and Phase II Study of GDC-0449 in Patients with Recurrent Glioblastoma Multiforme
Adult Brain Tumor Consortium
Brain tumorGDC-0449PBTC-025B
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma
Pediatric Brain Tumor Consortium 
Brain tumorABT-888PBTC-027
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors
Pediatric Brain Tumor Consortium
Brain tumorGDC-0449PBTC-025
A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449
Pediatric Brain Tumor Consortium 
Brain tumor18F- fluoromisonidazole (FMISO) as imaging agentACRIN-6684
Multicenter Phase II Assessment of Tumor Hypoxia in Glioblastoma Using 18F-Fluoromisonidazole (FMISO) with PET and MRI
American College of Radiology Imaging Network (ACRIN), with Brown University as biostatistics center
Breast cancer and other solid tumors1-Methyl-d-tryptophan
Ad.p53 DC vaccine
MCC-16025
A phase 1/2 study of Ad.p53 DC vaccine in combination with 1-methyl-D-tryptophan in metastatic solid tumors and invasive breast cancer
Moffitt Cancer Center and Research Institute
Breast cancerBevacizumab CALGB-40603
Randomized Phase II 2 x 2 Factorial Trial of the Addition of Carboplatin +/- Bevacizumab to Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer
Cancer and Leukemia Group B
Breast cancerBevacizumab SWOG-S0800
A Randomized Phase II Trial of Weekly Nanoparticle Albumin Bound Paclitaxel (Nab-Paclitaxel) (NSC-736631) With or Without Bevacizumab, Either Preceded By Or Followed By Q 2 Week Doxorubicin (A) And Cyclophosphamide (C) Plus Pegfilgrastim (Peg-G) as Neoadjuvant Therapy for Inflammatory and Locally Advanced Her-2/Neu Negative Breast Cancer
Southwest Oncology Group (SWOG)
Breast cancerGDC-0449 RO49290972009-099
A Phase I Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC # 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC # 749225) Administered in Patients with Advanced Breast Cancer
Wayne State University -Barbara Ann Karmanos Cancer Institute
Breast and gynecologic cancersCediranib
Olaparib
NCI # 8348, DFCI# 09293
Phase I/II study of cediranib and olaparib in combination for treatment of recurrent papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent triple-negative breast cancer
Dana-Farber Cancer Institute
Breast and gynecologic cancersABT-888UPCI 08-121
A Phase 1 Study of Chronically-Dosed, Single-Agent ABT-888 in Patients with BRCA ½ -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer
University of Pittsburgh Medical Center (UPMC)
Germ-cell cancersAlvocidibMSKCC-09034
A Non-Randomized Phase 2 Study of Alvocidib (Flavopiridol) Plus Oxaliplatin with or without 5-FU and Leucovorin for Relapsed or Refractory Germ-Cell Tumors
Memorial Sloan-Kettering Cancer Center
Gynecologic  cancersABT-888 Bevacizumab GOG-9923
A Phase I Study of Carboplatin/Paclitaxel/CTEP Supplied Agent Bevacizumab (NSC #704865, IND #7921) and CTEP Supplied Agent ABT-888 (NSC #737664 IND#77840) in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Gynecologic Oncology Group
Gynecologic cancersIxabepilone Bevacizumab  Temsirolimus  GOG-0086P
A Three Arm Randomized Phase II Study of Paclitaxel/Carboplatin/Bevacizumab (NSC#704865, IND#7921), Paclitaxel/Carboplatin/Temsirolimus (NSC#683864, IND#61010) and Ixabepilone (NSC#710428, IND#59699)/ Carboplatin/Bevacizumab as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Gynecologic Oncology Group
Hodgkin lymphomaTherapy adapted to results of PET scansSWOG-S0816
A Phase II Trial of Response-Adapted Therapy of Stage III-IV Hodgkin Lymphoma Using Early Interim FDG-PET Imaging
Southwest Oncology Group
LeukemiaVorinostat Gemtuzumab Ozogamicin AzacitidineFHCRC -2288.00
A Phase 1/2 Study of Vorinostat (Zolinza®) in Combination with Gemtuzumab Ozogamicin (Mylotarg®) and Azacitidine (Vidaza®) in Patients 50 Years of Age and Older with Relapsed/Refractory non-APL Acute Myeloid Leukemia (AML)
Fred Hutchinson Cancer Research Center 
Liver cancerSorafenib Bevacizumab NCCTG-N0745
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma
North Central Cancer Treatment Group
Liver cancerCixutumumab SorafenibCCC-PHI-64
A Phase I Trial of Escalating Doses of the Anti-IGF-1R Monoclonal Antibody IMCA12 and Standard Dose Sorafenib for Treatment of Advanced Hepatocellular Carcinoma
California Cancer Consortium
Lung cancer18F-FLT as PET imaging agent to assess preoperative therapyJ08134
Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-Small Cell Lung Cancer
Johns Hopkins University  
Lung cancerGDC-0449 CixutumumabECOG-E1508
A Randomized Phase II Study of Cisplatin and Etoposide in Combination with Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMCA12 for Patients with Extensive Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group 
Lung cancerCixutumumab CetuximabECOG-E4508
Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination with Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-Based Therapy
Eastern Cooperative Oncology Group 
MelanomaAZD6244MSKCC-09003
Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients with BRAF or NRAS Mutated Melanomas
Memorial Sloan-Kettering Cancer Center
MeningiomaRadiation or observationRTOG-0539
Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas
Radiation Therapy Oncology Group
MyelomaSCH 727965MC0888
Phase II Trial of Cdk Inhibitor SCH 727965 in Multiple Myeloma
Mayo Clinic Phase 2 Consortium
NeuroblastomaMonoclonal Antibody CH14.18COG-ANBL0931
A Comprehensive Safety Trial of Chimeric Antibody 14.18 (Ch14.18) with GM-CSF, IL-2 and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy
Children's Oncology Group 
Pancreatic cancerGDC-044909-068-B
A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients with Metastatic Pancreatic Cancer (10052747)
University of Chicago Phase 2 Consortium  
Prostate cancerCixutumumab TemsirolimusMSKCC-09117
Phase I/II Trial of Anti-IGF-IR Monoclonal Antibody IMC-A12 Plus mTOR Inhibitor Temsirolimus (CCI-779) in Metastatic Castration- Resistant Prostate Cancer (CRPC)
Memorial Sloan-Kettering Cancer Center  
SarcomasCixutumumab TemsirolimusMSKCC-09097
A Phase II Study of Temsirolimus (CCI-779, NSC 683864) and IGF-1 Receptor Antibody IMC-A12 (NSC 742460) in Patients with Metastatic Sarcomas
Memorial Sloan-Kettering Cancer Center  
Stomach and gastroesophageal cancersGDC-0449NYCC-09-0356
A Randomized, Double Blind Placebo Controlled Phase 2 Study of FOLFOX Plus or Minus GDC-0449 in Patients with Advanced Gastric and Gastroesophageal Junction (GEJ) Carcinoma
New York University Langone Medical Center / Montefiore (NY Phase 2 Consortium)    
Various solid tumors - PediatricCixutumumab TemsirolimusCOG-ADVL0813
A Phase I Study of IMC-A12 (Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody) in Combination with CCI-779 (Temsirolimus) in Pediatric Patients with Recurrent or Refractory Solid Tumors
COG Phase 1 Consortium
Various solid tumors - PediatricSeneca Valley virus-001COG-ADVL0911
A Phase 1 Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors with Neuroendocrine Features
Children's Oncology Group Phase 1 Consortium
Various solid tumorsABT-888OSU-09100
ABT-888 as monotherapy and in combination with Mitomycin C in patients with solid tumors with deficiency in homologous recombination repair
Ohio State University Medical Center
Various solid tumorsABT-888PCI-07-015
A Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies
University of Pittsburgh Medical Center (UPMC)/ U Pittsburgh Cancer Institute (UPCI)  
Various solid tumorsAZD6244  CixutumumabJ0691
A Phase 1, Single-Institution Open Label, Dose-Escalation Trial with an Expansion Cohort Evaluating the Safety and Tolerability of AZD6244 and IMC-A12 in Subjects with Advanced Solid Malignancies
Johns Hopkins University
Various solid tumorsAZD6244 09-005
Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers with BRAF Mutations Identified by Prospective Genotypic Analysis
Massachusetts General Hospital
Various solid tumorsCediranib
and whole brain radiation therapy
09-089
A Phase 1 Study of AZD2171 and WBRT in Patients with Brain Metastases
Massachusetts General Hospital, Dana-Farber Cancer Institute